TORONTO , Jan. 11, 2019 /CNW/ – Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF; FRA:1QS) (the “Company” or “Pure Global”) an integrated, growth-oriented life sciences and consumer products cannabis company, through its subsidiary PureSinse Inc. (“PureSinse”), is excited to announce that Health Canada has issued PureSinse a Sales License under the Cannabis Act.

Eligible and pre-registered Canadian medical patients can soon select from two dozen premium cannabis products offered by PureSinse, via its newly launched eCommerce website at PureSinse.com. The Company is committed to supporting medical cannabis patients by emphasizing the quality of and access to the products they need. The Company anticipates growing to 70 SKUs (stock-keeping units) by mid-2019, including adding extracted oil products, and vape pens.

PureSinse continues to demonstrate commitment to the medical community by leading one of the largest real-world evidence-based clinical studies in conjunction with the Appletree Medical Group and one of the largest Clinical Research Organizations in the world. The clinical data, which will be collected from thousands of patients, will provide necessary data points for guidance in the therapeutic benefits of specific cannabis strains for commonly reported medical symptoms. This evidence will guide PureSinse’s future pharmaceutical product and consumer product development plans and provide the medical community with published peer reviewed observational data on the efficacy of medical cannabis for a range of conditions.

As part of the Sales Licence, the Company can also sell products into the adult-legal consumer market through provincially licensed retailers, for which it is launching uniquely curated lines of consumer products tailored to specific market segments.

“This is a significant milestone for us and something we have been vigorously preparing for over the last several months,” said Malay Panchal, CEO of Pure Global. “We feel the medical community has been hugely underserviced with poor patient and physician education, and product offerings, areas we hope to be trail blazers in and make a significant contribution to in 2019,” added Mr. Panchal.

About Pure Global Cannabis

Pure Global Cannabis Inc. (TSX.V:PURE; OTC:PRCNF; FRA:1QS) is an innovation-based cannabis Company led by experienced pharma, biotechnology, horticultural, and consumer packaged goods (CPG) experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act. The Company’s Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. PURE will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates. The Company is using the Canadian market as a springboard to develop and manufacture GMP-compliant cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.

To register to Pure Global’s mailing list, please visit www.pureglobal.com. Follow @pureglobalcanna on Twitter and Facebook and @pureglobalcannabis on Instagram.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Florida Attorney To Sue Over Smoking Cannabis Ban
14 June 2017
This is How Many People Work in the Marijuana Industry
22 May 2018
Aphria Says Cannabis Will Be Sold Out Across Canada
13 October 2018